Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms

Inventors

Baloglu, Erkan • Austad, Brian C. • Roe, David G. • Leduc, Andrew • GOTTSCHLING, Stephen Edmund • Hecker, Evan

Assignees

Karyopharm Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12673939-B2

Patent

Publication Date

2026-07-07

Expiration Date


Abstract

The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

Core Innovation

The disclosed invention provides a scalable synthesis of Structural Formula (VII), designated eltanexor (KPT-8602, MB6), through Pd-catalyzed coupling of compounds (II) and (III), alongside an upstream route to compound (V). The disclosed synthesis and isolation sequence includes [procedural detail omitted for safety], producing crystalline Form I with 100% HPLC purity. The optimized process operates without requiring vigorous degassing or palladium scavenging, while achieving an overall yield of 81–86% compared with 26–49% for prior procedures.

The document also describes crystalline Forms I and II of Structural Formula (VII), with Form I characterized by specified x-ray powder diffraction peaks and Form II identified as a methanol solvate. It further encompasses methods for preparing crystalline Form I from Form II via solvent-mediated crystallization. The resulting crystalline forms are utilized in pharmaceutical compositions and for the treatment of CRM1-associated disorders.

Claims Coverage

The claim coverage includes four inventive features relating to Structural Formula (VII), its preparation, intermediate compound (V), and preparation of the crystalline form.

Crystalline form of Structural Formula (VII)

A crystalline form of the compound represented by Structural Formula (VII), characterized by x-ray powder diffraction peaks at 2θ angles of 4.6°, 22.8°, 23.2°, and 24.4°, with dependent claims further characterizing the form by additional diffraction peaks, a diffraction pattern, and a DSC thermogram feature.

Preparation of Structural Formula (VII)

A method of preparing the compound represented by Structural Formula (VII) by reacting compounds represented by Structural Formulas (II) and (III) in a solvent in the presence of a Pd catalyst and one or more inorganic bases, wherein further reaction details are [procedural detail omitted for safety] and dependent claims extend to upstream preparation of compounds (II), (IV), and (V).

Compound of Structural Formula (V)

A compound represented by Structural Formula (V), or a salt thereof.

Preparation of the crystalline form of Structural Formula (VII)

A method for preparing and isolating the specified crystalline form of Structural Formula (VII) from another crystalline form through crystallization, wherein the solvent-mediated sequence is [procedural detail omitted for safety].

The claim coverage encompasses four inventive features including crystalline Form I of Structural Formula (VII), its synthetic preparation via coupling of compounds (II) and (III), intermediate compound (V) or a salt thereof, and methods for preparing and isolating the crystalline form.

Stated Advantages

The synthesis provides an overall yield of 81–86%, compared with 26–49% for prior procedures.

The reported crystalline Form I has 100% HPLC purity.

Vigorous degassing and palladium scavenging are not required.

The reported optimization reduces side reactions and shortens cycle time.

The reported process provides reductions in catalyst loading, base and solvent volumes, temperature, and reaction time.

The process is reported to be selective and robust.

Documented Applications

Pharmaceutical compositions and treatment of CRM1-associated disorders.

Preparation and isolation of MB6/KPT-8602 represented by Structural Formula (VII), including crystalline Form I.

Preparation and isolation of the specified crystalline form of compound (VII) from another crystalline form.

Characterization of compound (VII) and its crystalline form using x-ray powder diffraction, DSC, chromatography, and NMR.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.